tislelizumab
beigene,novartis
#beigene announces late-breaking data at #esmogi22 showing overall survival benefit for #tislelizumab plus #chemotherapy in first-line advanced or #metastatic #esophagealsquamouscellcarcinoma $bgne 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.